A study of reported factor IX use around the world

Haemophilia

Volumn 17, Issue 3, 2011, Pages 446-455

  Stonebraker, J S ^a   Bolton Maggs, P H B ^b   Brooker, M ^c   Farrugia, A ^d,e   Srivastava, A ^f  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

^b MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^c WORLD FEDERATION OF HEMOPHILIA   (Canada)

^d Plasma Protein Therapeutics Association   (United States)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

Factor IX; Haemophilia B

Indexed keywords

BLOOD CLOTTING FACTOR 9;

ARTICLE; DEVELOPED COUNTRY; DRUG USE; ECONOMIC ASPECT; HEMOPHILIA B; HUMAN; PRIORITY JOURNAL; TREND STUDY;

DELIVERY OF HEALTH CARE; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; DRUG UTILIZATION; FACTOR IX; HEMOPHILIA A; HUMANS; INCOME; WORLD HEALTH;

EID: 79955158453     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2010.02461.x     Document Type: Article

References (54)

1. Evatt BL. Demographics of hemophilia in developing countries. Semin Thromb Hemost 2005; 31: 489-94.
2. Evatt BL. Observations from Global Survey 2001: an emerging database for progress. Haemophilia 2002; 8: 153-6.
3. Evatt BL, Robillard L. Establishing haemophilia care in developing countries: using data to overcome the barrier of pessimism. Haemophilia 2000; 6: 131-4.
4. Bohn RL, Schramm W, Bullinger M, Van den Berg M, Blanchette V. Outcome measures in haemophilia: more than just factor levels. Haemophilia 2004; 10(Suppl. 1): 2-8.
5. Farrugia A. Safety and supply of hemophilia products: worldwide perspectives. Haemophilia 2004; 10: 327-33.
6. O'Mahony B. WFH: back to the future. Haemophilia 2004; 10(Suppl. 4): 1-8.
7. O'Mahony B, Black C. Expanding hemophilia care in developing countries. Semin Thromb Hemost 2005; 31: 561-8.
8. Shapiro AD. A global view on prophylaxis: possibilities and consequences. Haemophilia 2003; 9(Suppl. 1): 10-8.
9. Skinner MW. WFH - the cornerstone of global development: 45years of progress. Haemophilia 2008; 14(Suppl. 3): 1-9.
10. Stonebraker JS, Amand RE, Nagle AJ. A country-by-country comparison of FVIII concentrate consumption and economic capacity for the global haemophilia community. Haemophilia 2003; 9: 245-50.
11. Aledort LM. Unsolved problems in haemophilia. Haemophilia 1998; 4: 341-5.
12. Isarangkura P. Haemophilia care in the developing world: benchmarking for excellence. Haemophilia 2002; 8: 205-10.
13. Lee CA. Towards achieving global haemophilia care - World Federation of Hemophilia programmes. Haemophilia 1998; 4: 463-73.
14. Ikkala E, Helske T, Myllylä G, Nevanlinna HR, Pitkänen P, Rasi V. Changes in the life expectancy of patients with severe haemophilia A in Finland in 1930-79. Br J Haematol 1982; 52: 7-12.
15. Poon M-C, Luke K-H. Haemophilia care in China: achievements of a decade of World Federation of Hemophilia treatment centre twinning activities. Haemophilia 2008; 14: 879-88.
16. Kirtava A, Soucie M, Evatt B, Mdivinishvili M, Abashidze M, Iosava G. National haemophilia programme development in the Republic of Georgia. Haemophilia 2005; 11: 529-34.
17. Larsson SA. Life expectancy of Swedish haemophiliacs, 1831-1980. Br J Haematol 1985; 59: 593-602.
18. Srivastava A, Chuansumrit A, Chandy M, Duraiswamy G, Karagus C. Management of haemophilia in the developing world. Haemophilia 1998; 4: 474-80.
19. Windyga J, Lopaciuk S, Stefanska E et al. Haemophilia in Poland. Haemophilia 2006; 12: 52-7.
20. Jones P. Haemophilia: a global challenge. Haemophilia 1995; 1: 11-3.
21. Antunes SV. Haemophilia in the developing world: the Brazilian experience. Haemophilia 2002; 8: 199-204.
22. Ayob Y. Management of hemophilia in resource-limited countries. Transfus Altern Transfus Med 2008; 10: 70-4.
23. Bolton-Maggs PHB. Optimal haemophilia care versus the reality. Br J Haematol 2005; 132: 671-82.
24. Evatt BL. The natural evolution of haemophilia care: developing and sustaining comprehensive care globally. Haemophilia 2006; 12(Suppl. 3): 13-21.
25. Srivastava A. Factor replacement therapy in haemophilia-are there models for developing countries? Haemophilia 2003; 9: 391-6.
26. Srivastava A. Choice of factor concentrates for haemophilia: a developing world perspective. Haemophilia 2001; 7: 117-22.
27. Tezanos Pinto M, Ortiz Z. Haemophilia in the developing world: successes, frustrations and opportunities. Haemophilia 2004; 10(Suppl. 4): 14-9.
28. Zhang L, Li H, Zhao H, Zhang X, Li L, Yang R. Retrospective analysis of 1, 312 patients with haemophilia and related disorders in a single Chinese institute. Haemophilia 2003; 9: 696-702.
29. Marketing Research Bureau, Inc. The Plasma Fractions Market in Asia and Pacific-2006. Orange, CT: Marketing Research Bureau, Inc, 2007a.
30. Marketing Research Bureau, Inc. The Plasma Fractions Market in the United States-2006. Orange, CT: Marketing Research Bureau, Inc, 2007b.
31. Marketing Research Bureau, Inc. The Plasma Fractions Market in Europe-2005. Orange, CT: Marketing Research Bureau, Inc, 2006.
32. Marketing Research Bureau, Inc. The Plasma Fractions Market in Central and South America-2004. Volumes A and B. Orange, CT: Marketing Research Bureau, Inc, 2005.
33. Marketing Research Bureau, Inc. The Plasma Fractions Market in the Middle East-2003. Orange, CT: Marketing Research Bureau, Inc, 2004.
34. World Federation of Hemophilia. Report on the Annual Global Survey 2006. Montreal, Canada: WFH, 2007.
35. World Federation of Hemophilia. Report on the Annual Global Survey 2005. Montreal, Canada: WFH, 2006.
36. World Federation of Hemophilia. Report on the Annual Global Survey 2004. Montreal, Canada: WFH, 2005.
37. World Federation of Hemophilia. Report on the WFH Global Survey 2003. Montreal, Canada: WFH, 2004.
38. World Federation of Hemophilia. Report on the WFH Global Survey 2002. Montreal, Canada: WFH, 2002.
39. Skinner M, Street A. Global data and haemophilia care trends: commentary. Haemophilia 2010; 16: 18-9.
40. United Nations. World Population Prospects: The 2006 Revision and World Urbanization Prospects: The 2005 Revision, New York, NY: UN, 2006.
41. World Federation of Hemophilia. Report on the WFH Global Survey 2001. Montreal, Canada: WFH, 2001.
42. World Federation of Hemophilia. WFH Global Survey on Hemophilia 2000 edition. Montreal, Canada: WFH, 2000.
43. World Federation of Hemophilia. WFH Global Survey on Hemophilia 1999 edition. Montreal, Canada: WFH, 1999.
44. World Bank Group. World Development Indicators 2007. (). Washington, DC: World Bank, 2007.
45. Organisation for Economic Co-operation and Development. The OECD, (). Paris, France: OECD, 2008.
46. Ewenstein BM, Heinrich Joist J, Shapiro AD et al. For the Mononine Comparison Study Group. Pharmacokinetic analysis of plasma-derived and recombinant FIX concentrates in previously treated patients with moderate or severe hemophilia B. Transfusion 2002; 42: 190-7.
47. Björkman S, Shapiro AD, Berntorp E. Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis. Haemophilia 2001; 7: 133-9.
48. Metzner HJ, Weimer T, Kronthaler U, Lang W, Schulte S. Genetic fusion to albumin improves the pharmacokinetic properties of factor IX. Thromb Haemost 2009; 102: 634-44.
49. Stonebraker JS, Bolton-Maggs PHB, Soucie JM, Walker I, Brooker M. A study of variations in the reported haemophilia B prevalence around the world. Haemophilia 2010; 16: 20-32.
50. Jenkins PV, Egan H, Keenan C et al. Mutation analysis of haemophilia B in the Irish population: increased prevalence caused by founder effect. Haemophilia 2008; 14: 717-22.
51. Stonebraker JS, Brooker M, Amand RE, Farrugia A, Srivastava A. A study of reported factor VIII use around the world. Haemophilia 2010; 16: 33-46.
52. Soucie JM, Evatt B, Jackson D, and the Hemophilia Surveillance System Project Investigators. Occurrence of hemophilia in the United States. Am J Hematol 1998; 59: 288-94.
53. Mehdizadeh M, Kardoost M, Zamani G, Baghaeepour MR, Sadeghian K, Pourhoseingholi MA. Occurrence of haemophilia in Iran. Haemophilia 2009; 15: 348-51.
54. Srivastava A, Hoots WK, Soucie JM, Ludlam CA. Linking the world with training and research for improving haemophilia care. Haemophilia 2008; 14(Suppl. 3): 43-8.